<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03936192</url>
  </required_header>
  <id_info>
    <org_study_id>EF 156</org_study_id>
    <nct_id>NCT03936192</nct_id>
  </id_info>
  <brief_title>A Parallel-group Active Comparator, Double-blind, Multicenter, Randomized, Double-blind, Phase III Clinical Study</brief_title>
  <acronym>SAVE</acronym>
  <official_title>A Parallel-group Active Comparator, Double-blind, Multicenter, Randomized, Double-blind, Phase III Clinical Study to Assess the Safety and Efficacy of Glucosamine Sulfate Plus Meloxicam Versus Glucosamine Sulfate Plus Chondroitin Sulfate in Treatment of Primary Symptomatic Knee Osteoarthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double-blind, parallel-group, placebo-controlled, and active-drug,
      12-week, multicenter clinical study. Participants will be randomized 2: 2: 1 to receive the
      combination of glucosamine sulfate + meloxicam (experimental group), combination of
      glucosamine sulfate + chondroitin sulfate (active control group) or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>glucosamine sulphate 1500mg + meloxicam 15mg, produced by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
Glucosamine sulfate 1500mg + Chondroitin sulfate 1200mg, produced by Zodiac Pharmaceutical Products S.A. (Condroflex®), given once daily for 12 weeks.
Placebo administered once daily for 12 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participant and Investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To assess whether the efficacy of glucosamine + meloxicam sulfate treatment is superior to the efficacy of treatment with glucosamine sulfate + chondroitin sulfate in improving pain in subjects with symptomatic primary knee OA treated for 4 weeks.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Absolute variation of the &quot;pain&quot; subscale score of the WOMAC questionnaire (0 to 100mm) 4 weeks (V2) after starting treatment in relation to the basal score (VR);</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">645</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>glucosamine sulfate 1500mg and meloxicam 15mg (Eurofarma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>glucosamine sulfate 1500mg plus meloxicam 15mg combination, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucosamine sulfate 1500mg plus Chondroitin Sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®), given once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucosamine sulphate 1500mg and meloxicam 15mg</intervention_name>
    <description>glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.</description>
    <arm_group_label>glucosamine sulfate 1500mg and meloxicam 15mg (Eurofarma)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg</intervention_name>
    <description>Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)</description>
    <arm_group_label>Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo administered once daily for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age of 40 to 75 years (both inclusive).

          2. Clinical and radiological diagnosis of primary (idiopathic) knee osteoarthritis
             according to the American College of Rheumatology (ACR) criteria.

          3. Radiological classification of Kellgren and Lawrence of grades 2 or 3 on X-ray of the
             target knee.

          4. Presence of painful symptoms in the target knee in the last 3 months due to
             osteoarthritis.

          5. Visual analogue scale for evaluation of knee osteoarthritis pain by the research
             participant ≥ 40 mm at the screening visit.

          6. Mean score ≥ 40mm on the &quot;pain&quot; subscale (0 to 100mm) on the target knee of the
             Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire
             at the randomization visit.

          7. ACR functional class from I to III.

          8. Signature of the Informed Consent Form before performing any study procedure.

        Exclusion Criteria:

          1. Diagnosis of septic arthritis, inflammatory arthritis (such as rheumatoid arthritis),
             gout, pseudogout, Paget's disease, dysplasias or congenital articular anomalies.

          2. Severe joint misalignment in the target knee, defined by the researcher.

          3. History of severe trauma or surgery (including arthroscopy) in the target knee within
             6 months prior to the study selection visit.

          4. Symptomatic osteoarthritis of the ipsilateral hip.

          5. Use of non-steroidal anti-inflammatory, dipyrone, opioid or narcotic analgesics,
             collagen and herbal remedies for osteoarthritis from the screening visit, or a washout
             period for such drugs less than those defined by the protocol, prior to the visit
             randomization. The use of antidepressants and pain modulating medicinal products
             should not be started from the screening visit, but they should be kept stable during
             the study if they are already being used prior to the screening visit.

          6. Oral, intravenous or intramuscular corticosteroid therapy within 30 days prior to
             study visit visit.

          7. Intra-articular injection of corticosteroids, hyaluronic acid and / or platelet-rich
             plasma at the target knee within 6 months prior to the study selection visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cassiano Berto</last_name>
    <phone>+551150908600</phone>
    <phone_ext>8412</phone_ext>
    <email>cassiano.berto@eurofarma.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Rodrigues</last_name>
    <phone>+551150908600</phone>
    <phone_ext>8417</phone_ext>
    <email>sandra.rodrigues@eurofarma.com.br</email>
  </overall_contact_backup>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>It is not yet known if there will be a plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

